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Introduction
Gestational diabetes mellitus (GDM) is the onset or
detection, for the first time, of any degree of glucose
intolerance during pregnancy [1–3]. The prevalence of
GDM, as reported in different studies, varies between
1% and 14% [4,5]. The differences in the prevalence of
GDM reported in these studies are as much due to eth-
nic and racial characteristics as it is to the screening pro-
tocols and diagnostic criteria used by the researchers in
question [6]. The two major approaches to screening are
universal and selective (or at-risk) screening [5]. Univer-
sal screening is more sensitive; selective screening is less
costly [7]. The risk factors used in selective screening are
set out in Table 1. Based on these risk factors, pregnant
women can be at low, average or high risk of developing
GDM [4,5,7]. With the selective approach, women at
low risk for GDM do not need to be screened [5].
Several teams have tried to improve the sensitivity
of selective screening by making the relevant protocols
more inclusive. Through this ‘tinkering’, age has emerged
as the most important risk factor for type II and, by
extension, gestational diabetes. Accordingly, the lower
threshold for screening has decreased from 30 years in
earlier studies [8] to 25 years in more recent ones [4,5].
We investigated the prevalence of GDM in our area
and tried to determine which of the aforementioned
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SUMMARY
Objective: We investigated the prevalence and outcome of gestational diabetes mellitus (GDM) in pregnant
Iranian women.
Materials and Methods: A total of 2,416 women, who were consecutive referrals for antenatal care to five univer-
sity teaching hospitals in Tehran, were recruited. Patients with known diabetes were excluded. All 2,416 women
were screened with a 50-g 1-hour glucose challenge test, and any woman with a plasma glucose concentration
more than or equal to 130 mg/dL was given a 100-g 3-hour glucose tolerance test. Diagnosis of GDM was accord-
ing to Carpenter and Coustan’s criteria. The remainder served as controls for the study.
Results: There were 114 women (4.7%; 95% confidence interval [CI], 3.9–5.6%) who had GDM. Women with
GDM had a significantly higher parity and body mass index than non-diabetic women. Women with GDM were
also more likely to have a family history of diabetes and a history of poor obstetric outcome. Of the 114 women,
27 (23.6%) were younger than 25 years old, and 16 (14.0%) had no recognizable risk factor for diabetes. The
odds ratio (OR) for cesarean section (OR, 2.28; p = 0.0002), macrosomia (OR, 1.93; p = 0.0374), neonatal
hypoglycemia (OR, 3.2; p = 0.011) and hypocalcemia (OR, 3.045; p = 0.0195), and still birth (OR, 4.8; p = 0.003)
were all significantly higher in women with GDM than non-GDM controls.
Conclusion: One out of every 20 pregnant Iranian women will develop GDM, with significantly increased odds
of adverse maternal and fetal outcome. The significant proportion of young and/or risk factor-free women in
our sample means that there seems to be a case for universal GDM screening in pregnant Iranian women.
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screening approaches would be more appropriate,
taking maternal and fetal outcomes into account, for
our population and others with a similar socio-
economic and GDM profile.
Materials and Methods
Setting
In a cross-sectional study carried out in five teaching
hospitals affiliated to Tehran University of Medical
Sciences, all women referred to the antenatal clinics at
the aforementioned hospitals were enrolled in our study
over a period of 2 years and screened for GDM. Patients
with known diabetes were excluded from the study.
Methods
Universal screening consisted of a 50-gram 1-hour glu-
cose challenge test (GCT). Every woman attending the
antenatal clinic was screened in this way between the
24th and 28th week of her pregnancy. If any woman was
found to have one or more risk factors [6] for diabetes
during her first antenatal visit, she was screened during
the same visit. If her plasma glucose on screening was
equal to or greater than 130 mg/dL, she underwent a
100-g 3-hour oral glucose tolerance test (OGTT) to
confirm the diagnosis of GDM, as defined by the crite-
ria proposed by Carpenter and Coustan [6,9].
Screening and diagnostic tests were repeated
between the 30th and 32nd weeks in patients with at
least one abnormal reading on 100-g 3-hour OGTT,
symptoms of hyperglycemia (polydipsia, polyuria), gly-
cosuria, polyhydramnios, or proteinuria. Polydipsia is
defined as a primary increase in water intake or sensa-
tion of dry mouth [10]. Polyuria is defined as urine
output exceeding 3 litres per 24 hours [10]. Glycosuria
is defined as any quantity of glucose that is detected in
urine [10]. Polyhydraminios (or hydramnios) is defined
as excessive amniotic fluid of more than 2,000 mL of
amniotic fluid [11]. Proteinuria is defined as 300 mg or
more of urinary protein per 24 hours or 100 mg/dL or
more in at least two random urine specimens collected
6 or more hours apart [11]. Blood sampling took
place in the participating clinics by trained personnel
under the supervision of a trained midwife. All blood
samples were centrifuged no more than 30 minutes,
sampled, refrigerated, and then transferred at the end
of every day under appropriate storage conditions to
Doctor Shariati Hospital. Measurement was by the
glucose oxidase method, using a Hitachi 704 auto-
analyzer. Each participant completed a questionnaire,
which recorded the results of a general medical exami-
nation and any relevant obstetric or endocrine history.
Every patient was followed up until delivery at the clinic
whenever possible or otherwise by phone or mail.
The 2,416 women recruited were divided into four
groups based on the results of a two-step screening
approach: a 50-g GCT followed, if positive, by a 100-g
OGTT. Women with a positive GCT test and two or
more abnormal OGTT readings were diagnosed with
GDM. Women with a single abnormal OGTT reading
were classified in the impaired glucose tolerance (IGT)
group. Women with an abnormal GCT but a normal
OGTT were classified in the impaired GCT (IGCT)
group. Women with a normal GCT were classified as
normal. The women were also divided into three age
groups (Table 3). Body mass index (BMI) was used as
an index of obesity.
Statistical analysis
The data gathered were analyzed according to the
National Diabetes Data Group (NDDG) criteria and
then compared with results obtained with Carpenter
and Coustan’s criteria for diagnosis of GDM.
We also compared the universal screening approach
with the at-risk screening approach to determine the
proportion of cases that would be missed with the lat-
ter method.
Prevalence rates were calculated all four diagnostic
groups and selected risk-factor groups. The chi-square
test was carried out to test the difference between two
proportions and Fisher’s exact test for contingency tables
with minimum expected frequencies of less than 5. Odds
ratios (ORs) with a 95% confidence interval (CI) were
Table 1. Age distribution of 2,416 women surveyed for gestational diabetes mellitus (GDM)
GDM*, IGT, IGCT, Normal Total, AAP-GDM,
Age
n (%) n (%) n (%) pregnancy, n (%) n (%) %
15–24 27 (23.6) 21 (30.0) 155 (41.9) 1,006 (54.0) 1,209 (50.0) 2.23
25–34 56 (49.1) 39 (55.7) 166 (44.9) 740 (39.7) 1,001 (41.4) 5.59
35–45 31 (27.2) 10 (14.3) 49 (13.2) 116 (6.2) 206 (8.5) 15.04
Total 114 (100) 70 (100) 370 (100) 1,862 (99.9†) 2,416 (99.9†) 4.71
*Diagnosis based on Carpenter and Coustan’s criteria [9]; †less than 100% because of rounding errors. IGT = impaired glucose tolerance; IGCT = impaired glu-
cose challenge test; AAP-GDM = age-adjusted GDM prevalence.
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calculated. All p values were for two-tailed tests, with the
level of significance set at 0.05. All statistical analyses
were performed using SPSS version 10.0 software.
Results
A total of 2,416 women were enrolled in this study. Of
these, 114 (4.7%) had GDM, 70 (2.9%) had a single
abnormal OGTT reading (IGT), 370 (15.3%) had an
abnormal GCT only (IGCT), and 1,862 had a normal
screening test (Figure).
The prevalence of GDM in our sample was 4.7%
(95% CI, 3.91–5.64%) using Carpenter and Coustan’s
criteria, and 3.97% using NDDG criteria. The difference
in prevalence was not statistically significant (χ2 = 2.82,
p =0.0918). The mean age (and standard deviation) was
29.09 ± 6.13 years in women with GDM, 27.73 ± 5.97
years in women with IGT, 26.72 ± 6.0 years in women
with IGCT, and 24.92 ± 5.31 years in normal women.
Women with GDM were significantly older (p < 0.0001)
than women in the other three groups. The age distri-
bution and GDM prevalence in each age group are
shown in Table 1. The relative prevalence of GDM with
respect to the 25–34 age group was 0.39 in the 15–24
age group and 2.68 in the 35–45 age group. Demo-
graphic features and relevant obstetric history for the
normal and GDM groups are given in Table 2.
Mean BMI was 27.43 ± 4.33 kg/m2 in the GDM
group, 25.44 ± 2.11 kg/m2 in the IGT group, 24.98 ±
2.11 kg/m2 in the IGCT group, and 24.78 ± 2.09 kg/m2
in normal women. There was a significant difference
(F = 48.815, p < 0.0001) in BMI between women with
GDM and women in the other three groups. The preva-
lence of obesity, as defined by a BMI of more than 27,
was 35% in the GDM group, compared with 11.3% in
normal women (p < 0.0001).
There were 33.33% of women with GDM who had
a positive family history of diabetes, compared with
10.3% of women in the normal group (p < 0.0001).
Of the 114 women with GDM, 28 (24.5%) had a
history of spontaneous abortion, 9 (7.9%) had a history
of premature labor, and 29 (25.4%) had previously
given birth to a macrosomic child. The mean fasting
blood sugar was 93.73 ± 20.41 mg/dL (5.43 ± 1.13
mmol/L) in GDM women, 87.34 ± 15.12 mg/dL (4.85 ±
0.84 mmol/L) in IGT women, 75.29 ± 10.92 mg/dL
(4.18 ± 0.61 mmol/L) in IGCT women, and 73.19 ±
11.02 mg/dL (4.11 ± 0.61 mmol/L) in normal women.
The difference in the mean fasting blood sugar between
women with GDM and women in the other three groups
was statistically significant (p < 0.0001). Glycosuria was
detected in 34.21% of women with GDM, compared
with 3.8% of women with a normal screening test
(p = 0.0001, χ2 = 196.67).
Compared with women with a normal screening
test, women with GDM had significantly higher parity
and BMI, as well as more frequent family history of
diabetes and of adverse obstetric outcome. Overall,
86% of women with GDM had one or more risk factors
for diabetes; that is to say, 14% of women with GDM
in our sample would have been “missed” if selective
screening had been used. Table 3 shows that the odds
ratio for cesarean section (OR, 2.28; p = 0.0002),
macrosomia (OR, 1.93; p = 0.0374), and neonatal
hypoglycemia (OR, 3.2; p = 0.011) and hypocalcemia
(OR, 3.045; p = 0.0195), and still birth (OR, 4.8; p =
0.003) were all significantly higher in women with GDM
than non-GDM controls. There was no significant dif-
ference in incidence of neonatal hyperbilirubinemia,
preeclampsia, and respiratory distress syndrome between
the two groups. The sensitivity of NDDG criteria com-
pared with Carpenter and Coustan’s criteria was 84.2%
to GDM detection, and using of this criteria was accom-
panied with loss to detect 5% of cesarean sections, 16%
of macrosomia, 15% of hypoglycemia, and 12.5% of
hypocalcemia in GDM patients. There were no signifi-
cant differences between two criteria in incidence of
other pregnancy outcomes in GDM patients.
Discussion
The prevalence of GDM varies across the globe. High
prevalence rates have been reported in studies from
Australia (Indian-born 15%, Chinese 13.9%) and the
United States (Zuni Indians 14.3%). The prevalence
also varies between racial and ethnic groups within 
the same country. Only 1.5–2% of Midwestern white
7.6%
abnormal
OGTT
77.0%
normal
GCT
16.3%
abnormal
GCT but
normal OGTT 
2.9% single 
abnormal
OGTT reading
4.7%
confirmed
GDM
Figure. Prevalence of impaired glucose tolerance and gesta-
tional diabetes mellitus (GDM) in 2,416 pregnant Iranian
women. GCT = glucose challenge test; OGTT = oral glucose
tolerance test.
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women develop GDM, while up to 15% of Native
American women from southwestern USA have been
reported to develop GDM. In the Hispanic, African-
American and Asian populations of the USA, the inci-
dence of GDM is 5–8% [11,12].
Statistical variations are partly due to differences in
the screening criteria and protocols used. Furthermore,
the prevalence of GDM is strongly influenced by race
and culture. The figure of 4.7% obtained in this study
represents a moderate prevalence rate, compared with
Table 2. Demographic features of 2,416 women assessed for gestational diabetes mellitus (GDM)
Subjects* Normal† GDM Adjusted 
Characteristic (n = 2,416), (n = 1,862), (n = 114), odds ratio p‡
n (%) n (%) n (%) (95% CI)
Maternal age
15–24 1,209 (50.0) 1,006 (83.2) 27 (2.2) 0.10 (0.06–0.17) < 0.0001
25–34 1,001 (41.4) 740 (73.9) 56 (5.6) – –
35–45 206 (8.5) 116 (56.3) 31 (15.0) 9.96 (5.74–17.27) < 0.0001
BMI (kg/m2)
≤ 27 2,154 (89.2) 1,651(76.6) 74 (3.4) – < 0.0001
> 27 262 (10.8) 211 (80.5) 40 (15.3) 4.23 (2.80–6.37) –
Abortion**
Yes 292 (12.1) 176 (60.3) 86 (30.5) 3.12 (1.98–4.91) < 0.0001
No 2,124 (87.9) 1,686 (79.4) 28 (1.3) – –
Delivery < 37 weeks§
Yes 92 (3.8) 60 (65.2) 9 (9.8) 2.57 (1.24–5.33) 0.015
No 2,324 (96.2) 1,802 (77.5) 105 (5.0) – –
Macrosomia (> 4,000 g)§
Yes 128 (5.3) 64 (50.0) 29 (22.7) 9.58 (5.8–15.6) < 0.0001
No 2,288 (94.7) 1,798 (78.6) 85 (3.7) – –
Parity
Nulliparous 1,195 (49.5) 997 (83.4) 47 (3.9) – –
Multiparous 1,221 (50.5) 865 (70.8) 67 (5.5) 1.56 (1.07–2.31) 0.024
FH of diabetes
Yes 296 (12.3) 192 (64.9) 38 (12.8) 4.34 (2.86–6.60) < 0.0001
No 2,120 (87.7) 1,670 (78.8) 76 (3.6) – –
*All pregnancies; †normal pregnancy: women with a normal screening test (glucose challenge test), Table 1; ‡two-sided Fisher’s exact test in every case; §previous
history. CI = confidence interval; BMI = body mass index; FH = family history in first-degree relative.
Table 3. Pregnancy and neonatal outcomes in 114 women with gestational diabetes mellitus (GDM) and non-GDM 
controls
Frequency, % (95% CI)
Complication
GDM Controls
OR (95% CI) p
Cesarean section 47.13 (36.33–58.13) 28.1 (26.71–29.52) 2.28 (1.48–3.49) 0.0002
Preeclampsia 4.38 (1.4–9.9) 2.01 (1.4–2.8) 2.14 (0.8–5.5) 0.1
Still birth 5.2 (1.9–11.1) 1.12 (0.7–1.7) 4.8 (1.9–12.3) 0.003
Macrosomia 15.8 (9.09–25.52) 9.00 (8.13–9.93) 1.93 (1.08–3.47) 0.0374
Neonatal hypoglycemia 11.49 (5.65–20.12) 3.9 (3.32–4.55) 3.2 (1.62–6.3) 0.0011
Neonatal hypocalcemia 7 (2.57–14.41) 2.7 (2.22–3.25) 3.045 (1.29–7.16) 0.0195
Neonatal hyperbilirubinaemia 12.64 (6.48–21.5) 7.4 (6.61–8.26) 1.81 (0.95–3.4) 0.1031
Neonatal respiratory distress syndrome 1.75 (0.2–6.1) 0.4 (0.19–0.8) 4.13 (0.8–19.7) 0.1
CI = confidence interval; OR = odds ratio.
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figures reported elsewhere. The results of our study con-
firm the findings of other studies performed in the
urban population of Iran [13,14]. In a study of 820 rural
Tehrani women living in 108 villages outside the munici-
pal boundary of the city of Tehran, the prevalence of
GDM was calculated as 2.3% using NDDG criteria and
a cutoff point of 140 mg/dL for GCT screening. In this
study, 63% of the women with GDM were aged less
than 30 years [15]. Assuming that a rural population has
a significantly different lifestyle, the calculated preva-
lence of GDM in our study of an essentially urban popu-
lation, using the same criteria and threshold, would
come to 3.5%. Screening for GDM during pregnancy is
recommended, because less than 20% of women with
significant gestational glucose intolerance will have overt
evidence of disease (glycosuria, polyuria, and polydip-
sia). In our study, 34.2% of the women with GDM had
glycosuria, and 31% had at least one symptom of
hyperglycemia (polyuria, hyperhidrosis, polydipsia, and
polyphagia). In addition, 52% of women with a normal
screening test also had one or more of these symptoms,
underlining the low sensitivity of screening solely based
on symptoms.
The best approach to screen for GDM remains a con-
troversy. Many sources, including the American Diabetes
Association, recommended universal screening in the
past [16], but selective screening is more cost-effective
in low-prevalence populations. Universal screening
remains the approach of choice in populations with a
moderate or high prevalence of GDM [8,17].
Metzger and Coustan stated that unless one decides
there is no benefit to GDM diagnosis, there may be
some populations in which universal screening makes
sense and other populations in which it does not, and
that this may be the best way of deciding which of the
aforementioned screening strategies to adopt [1].
Solomon et al [18] used a risk-scoring system based
on age, BMI, and ethnicity. Patients with a low score
comprised 35% of their sample and had a GDM preva-
lence of less than 1%. However, the probability of detect-
ing GDM depends on the a priori risk, and the time from
the last meal to the start of the glucose challenge test
affects the criteria that should be used for reporting a
positive test. In other populations, approximately one-
fifth of the women were lean and could be excluded
from screening, with screening tests identifying more
than 90% of women with GDM. The use of selective
guidelines would exclude 20% of women in Australia and
10% of women in the US, and would miss approximately
3% of women with GDM [19].
Although the US Preventive Services Task Force con-
cluded that there was insufficient evidence to recom-
mend universal screening for GDM, more than 90% of
obstetricians reported screening all their patients [15].
Cost analysis of screening and diagnostic methods
based on this population were in favor of universal
screening [20].
If selective screening criteria were applied to our
sample, 14% of women with GDM would be missed.
Nevertheless, the choice between universal and targeted
screening remains unclear. In our sample, however, the
significant prevalence of GDM among women without
any risk factor for diabetes does not support the adop-
tion of risk factor-based screening in our population.
One important issue that remains to be determined
is the correlation between maternal glycemia and various
pregnancy outcomes. Assuming this association can be
mathematically defined, the HAPO study should eventu-
ally be able to find it [21]. The association between
overt GDM and adverse pregnancy outcome is a matter
of consensus; however, data from the literature do not
unequivocally support this [22]. It is probable that in
situations where the standard of obstetric care provided
is sufficient to mitigate many of the potential hazards of
maternal hyperglycemia, the likelihood of significant
differences being observed becomes far smaller [21]. In
other words, as obstetric care improves, it will become
increasingly difficult to use GDM pregnancy outcome
as an endpoint [21]. An interesting approach, statisti-
cally, is the one used by Schmidt et al, that is using popu-
lation attributable fraction to determine the percentage
of adverse events that can be directly attributed to, in
their case, GDM [23]. Their results, which were signifi-
cant in that Brazil, like Iran, is a country in epidemiologic
transition, showed that a very low proportion of the
adverse pregnancy outcome observed could be directly
attributed to GDM. This is worthy of further investiga-
tion, as it casts doubt on the cost-effectiveness of
national universal screening programs, like ours. The
point is this: with the prevalence of type II diabetes
increasing across the world, and given that the preva-
lence of GDM is thought to shadow that of type II dia-
betes, most populations will expect to see a rise in GDM
figures during the coming years. The anticipated increase
in adverse pregnancy outcomes may or may not be miti-
gated by improved obstetric care, but the cost of provid-
ing this care will increase as the number of pregnancies
at risk increases. Furthermore, mothers with GDM are
likely to become mothers with type II diabetes in the
future. The question is: will they ever be more motivated
to make the necessary preventive lifestyle changes than
when they are carrying their child? We purport that the
value of universal screening in populations like ours
extends far beyond the safe negotiation of a high-risk
pregnancy. Rather, it represents an ideal point at which
to screen a significant proportion of the population
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for a disease that usually remains silent until irreversible
complications set in.
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